Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Wade Clapp

Showing results (111-120 of 117) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 117 results.
The New England Journal of Medicine|March 19, 2020
Selumetinib in Children with Inoperable Plexiform NeurofibromasAndrea M Gross, Pamela L Wolters, Eva Dombi, et al.
The Lancet. Oncology|October 27, 2012
Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trialKent A Robertson, Grzegorz Nalepa, Feng-Chun Yang, et al.
Plos One|June 14, 2018
Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2, Robert Allaway, Steve P Angus, et al.
Nature Medicine|January 14, 2021
Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trialMichael J Fisher, Chie-Schin Shih, Steven D Rhodes, et al.
American Journal of Medical Genetics. Part A|January 21, 2014
CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapiesBrigitte C Widemann, Maria T Acosta, Sylvia Ammoun, et al.
Nature Medicine|January 6, 2025
Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trialAndrea M Gross, Geraldine O'Sullivan Coyne, Eva Dombi, et al.
Plos One|July 15, 2021
Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALKLong-Sheng Chang, Janet L Oblinger, Abbi E Smith, et al.
Pageof 12

Showing results (111-120 of 117) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 117 results.
The New England Journal of Medicine|March 19, 2020
Selumetinib in Children with Inoperable Plexiform NeurofibromasAndrea M Gross, Pamela L Wolters, Eva Dombi, et al.
The Lancet. Oncology|October 27, 2012
Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trialKent A Robertson, Grzegorz Nalepa, Feng-Chun Yang, et al.
Plos One|June 14, 2018
Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2, Robert Allaway, Steve P Angus, et al.
Nature Medicine|January 14, 2021
Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trialMichael J Fisher, Chie-Schin Shih, Steven D Rhodes, et al.
American Journal of Medical Genetics. Part A|January 21, 2014
CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapiesBrigitte C Widemann, Maria T Acosta, Sylvia Ammoun, et al.
Nature Medicine|January 6, 2025
Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trialAndrea M Gross, Geraldine O'Sullivan Coyne, Eva Dombi, et al.
Plos One|July 15, 2021
Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALKLong-Sheng Chang, Janet L Oblinger, Abbi E Smith, et al.
Pageof 12